Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Abstract Background With the increased use of isocitrate dehydrogenase (IDH) inhibitors in acute myeloid leukemia (AML) and cholangiocarcinoma, the toxicity of these drugs is a growing concern. This study aimed to evaluate the adverse events (AEs) of IDH inhibitors based on the Food and Drug Adminis...
Saved in:
Main Authors: | Ximu Sun, Han Zhou, Yanming Li, Yanhui Luo, Qixiang Guo, Yixin Sun, Chenguang Jia, Bin Wang, Maoquan Qin, Peng Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-02-01
|
Series: | Future Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43094-025-00769-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01) -
The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yue Zhou, et al.
Published: (2025-01-01) -
Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
by: Chuang Yang, et al.
Published: (2025-02-01) -
Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
by: Wenchao Lu, et al.
Published: (2025-01-01) -
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01)